Literature DB >> 126566

Peptidoglycan adjuvants: minimal structure required for activity.

A Adam, F Ellouz, R Ciorbaru, J F Petit, E Lederer.   

Abstract

The chemical structure of the adjuvant active fraction of mycobacterial cell walls has been investigated. It had been shown previously that soluble peptidoglycan fragments obtained from cell walls of Mycobacteria by lysozyme digestion or by other treatments act as adjuvants for increasing both humoral and cellular immunity. We then found that even the monomer subunit of the peptidoglycan of Mycobacteria (i.e. a disaccharide-tetrapeptide) is adjuvant active; then, similar compounds from other strains of bacteria were tested; the monomeric subunits of meso-diaminopimelic acid as well as L-lysine containing peptidoglycans were found to be adjuvant active. The smallest active compound studied so far is N-acetyl-muramyl-L-alanyl-D-isoglutamine synthesized for us by SINAY et al. (1975).

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 126566

Source DB:  PubMed          Journal:  Z Immunitatsforsch Exp Klin Immunol        ISSN: 0300-872X


  10 in total

1.  NOD2 modulates immune tolerance via the GM-CSF-dependent generation of CD103+ dendritic cells.

Authors:  David Prescott; Charles Maisonneuve; Jitender Yadav; Stephen J Rubino; Stephen E Girardin; Dana J Philpott
Journal:  Proc Natl Acad Sci U S A       Date:  2020-04-29       Impact factor: 11.205

Review 2.  Unleashing the therapeutic potential of NOD-like receptors.

Authors:  Kaoru Geddes; João G Magalhães; Stephen E Girardin
Journal:  Nat Rev Drug Discov       Date:  2009-06       Impact factor: 84.694

Review 3.  Unleashing the potential of NOD- and Toll-like agonists as vaccine adjuvants.

Authors:  Charles Maisonneuve; Sylvie Bertholet; Dana J Philpott; Ennio De Gregorio
Journal:  Proc Natl Acad Sci U S A       Date:  2014-08-18       Impact factor: 11.205

4.  Failure of synthetic muramyl dipeptide to increase antibacterial resistance.

Authors:  H Finger; C H Wirsing von König
Journal:  Infect Immun       Date:  1980-02       Impact factor: 3.441

Review 5.  Muramyl peptides. Chemical structure, biological activity and mechanism of action.

Authors:  A Adam; J F Petit; P Lefrancier; E Lederer
Journal:  Mol Cell Biochem       Date:  1981-12-04       Impact factor: 3.396

6.  Relationships between adjuvant, immunosuppressive, and mitogenic activities of staphylococcal peptidoglycan.

Authors:  R Dziarski
Journal:  Infect Immun       Date:  1979-11       Impact factor: 3.441

7.  Peptide length requirement for experimental allergic encephalomyelitis in guinea pigs.

Authors:  S Levit; J M Powers; D Milek; S W Brostoff
Journal:  Neurochem Res       Date:  1980-01       Impact factor: 3.996

8.  Adjuvant disease induced by mycobacteria, determinants of arthritogenicity.

Authors:  F Audibert; L Chedid
Journal:  Agents Actions       Date:  1976-02

Review 9.  Harnessing the untapped potential of nucleotide-binding oligomerization domain ligands for cancer immunotherapy.

Authors:  Sanja Nabergoj; Irena Mlinarič-Raščan; Žiga Jakopin
Journal:  Med Res Rev       Date:  2018-12-13       Impact factor: 12.944

10.  Human NOD2 Recognizes Structurally Unique Muramyl Dipeptides from Mycobacterium leprae.

Authors:  Mirjam Schenk; Sebabrata Mahapatra; Phuonganh Le; Hee Jin Kim; Aaron W Choi; Patrick J Brennan; John T Belisle; Robert L Modlin
Journal:  Infect Immun       Date:  2016-08-19       Impact factor: 3.441

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.